+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID07121036

Phase 1 Study of High-Dose Intravenous Vitamin C Combined With Standard Treatment for Advanced Malignant Solid Tumors Evaluating Different Dosage Regimens Based on Vitamin C Pharmacokinetics

Led by Zhongnan Hospital · Updated on 2025-08-13

18

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the use of high-dose vitamin C HDVC given intravenously in patients with advanced malignant solid tumors who are also receiving standard systemic anti-tumor treatments. Vitamin C is essential for the body and may have anti-tumor effects, especially when given at high doses intravenously. Past research suggests that maintaining higher blood concentrations of vitamin C for longer periods might improve its potential anti-cancer effects, which this study aims to explore further with different dosing schedules. Participants receive HDVC intravenously in three different regimens 0.5 grams per kilogram once daily, 0.5 grams per kilogram twice daily, or 0.75 grams per kilogram twice daily. Each regimen is given continuously for 5 to 7 days during the first cycle of their standard systemic cancer therapy. Researchers will measure vitamin C blood levels daily to understand how different dosing affects vitamin C concentration in the body. During the study, participants will be monitored closely with daily blood tests to track vitamin C levels and assess how the vitamin behaves in the body over time. The main outcome is to study the pharmacokinetics of these dosing regimens from baseline through day 7. The study aims to find the best way to combine HDVC with standard cancer treatments to optimize potential benefits. The total participation period covers the first treatment cycle and vitamin C administration days, with ongoing evaluation of safety and effects.

CONDITIONS

Brief Title

High - Dose Vitamin C Infusion Regimen Based on Pharmacokinetic Characteristics for Patients With Advanced Malignant Solid Tumors

Research Team

L

Lei Yang, Dr

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here